Qsymia and a history of kidney stones: what the label actually says

Qsymia can be associated with kidney stones because it contains topiramate. Its label reports a higher nephrolithiasis rate in one adult dose group than in placebo during one-year trials, but a past stone is not listed as an across-the-board contraindication. A clinician needs the stone history and current kidney-related record before deciding whether this product fits an individual.¹

The question is more precise than “does Qsymia cause stones?” It is whether an earlier stone, its type and circumstances, kidney history, and other medicines change the benefit-risk discussion for this particular combination product. Qsymia joins phentermine with extended-release topiramate. The stone warning belongs to the topiramate component; a phentermine-only comparison cannot transfer this warning to every weight-loss prescription.¹

Read the trial numbers with their denominators

In the label’s one-year adult studies, nephrolithiasis was reported in 0.2% of participants assigned 7.5 mg/46 mg, 1.2% assigned 15 mg/92 mg, and 0.3% assigned placebo. These are event proportions in trial arms, not a formula for predicting a person’s probability. They do not tell a reader whether a stone occurred in someone with the same history, anatomy, hydration pattern, or concurrent medicines.¹

The label explains a plausible mechanism: topiramate can reduce urinary citrate and increase urinary pH. It also flags concurrent carbonic-anhydrase inhibitors and a ketogenic diet as factors relevant to the stone discussion. A history of stones therefore merits a product-specific review even when a person has taken another weight medicine without trouble. The label does not supply a simple history-based “yes/no” rule, a stone-size cutoff, or an at-home prevention protocol.¹

Separate a label warning from an individual decision

The label’s contraindications are formal situations in which the drug should not be used. Its warnings identify risks that require evaluation and monitoring. Kidney stones appear under a warning, not as a blanket prohibition for anyone who once had one. Conversely, that distinction is not a green light to overlook an earlier episode. A prescriber can review the actual records and determine whether further assessment or another treatment discussion is needed.¹

This is also why a general GLP-1 stone-signal article does not answer the Qsymia question: the products, evidence, and possible pathways differ. A clinic should identify the exact proposed medication before discussing safety. If a site says only “medical weight loss,” ask which product it means, who reviews the drug history, and how a new symptom reaches a clinician.

If a symptom is already present

Qsymia’s patient information says to contact the healthcare provider for severe side or back pain or blood in the urine, which can be signs of a kidney stone. An online description cannot tell whether those symptoms are caused by Qsymia, a stone, or something else. Keep the actual symptom onset, location, and any test result together for the treating clinician rather than attributing it from timing alone.¹

For a consultation, a useful final question is: “What in my prior stone record changes the assessment of Qsymia specifically, and what other weight-management options would meet my goal?” A medical weight-management provider directory can help locate services; the individual prescriber must make the clinical determination.